Bart De Strooper
From Wikipedia, the free encyclopedia
Bart De Strooper is a Belgian molecular biologist and professor at Vlaams Instituut voor Biotechnologie and KU Leuven (Leuven, Belgium) and the UK Dementia Research Institute and University College London, UK. De Strooper's research seeks to translate genetic data into the identification and treatment of neurodegenerative diseases and treatments. interest are the secretases, proteases which cleave the amyloid precursor protein (APP), resulting in amyloid peptides.
De Strooper obtained an MD at the KU Leuven in 1985 and a PhD in 1992. He would go on to complete his postdoc at the European Molecular Biology Laboratory (EMBL) in Heidelberg Germany under Dr. Carlos Dotti.[1] De Strooper returned to his alma mater in 1999, joining the VIB Center for the Biology of Disease, now known as the VIB-KU Leuven Center for Brain & Disease Research. Along with continued advancement in neurodegenerative diseases, De Strooper became the center's Departmental Director in 2007, leading over 250 neuroscience researchers.[2] He would also serve as a Professor of Neurodegenerative Diseases at University College London.[1]
In December 2016 he became the director of the UK Dementia Research Institute (DRI) at University College London.[3] Under De Strooper's leadership, the DRI "established seven major research centres, recruited over 60 Principal Investigators, and built a community of 800-plus researches".[4] De Strooper voluntarily stepped down from the role in November 2022, citing a desire to focus on dementia and translational neuroscience at the UCL Queen Square Institute of Neurology. He continues to collaborate with the Academy of Medical Sciences fellowship, to which he was elected to in 2020.
.svg){kind=small}
